Arch Biopartners Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ARCH.V research report →
Price Chart
About the company
Arch Biopartners Inc. is a biotechnology firm dedicated to devising groundbreaking solutions for both medical and commercial applications. A significant focus for the company is the advancement of Metablok, a key therapeutic agent designed to address or avert dipeptidase-1 driven inflammation in critical organs such as the lungs, liver, and kidneys.
- CEO
- Richard Gabriel Muruve
- IPO
- 2010
- Employees
- 6
- HQ
- Toronto, ON, CA
Get TickerSpark's AI analysis on ARCH.V
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $68.61M
- P/E
- -25.77
- PEG
- 0.49
- P/S
- 0.00
- P/B
- -18.55
- EV/EBITDA
- -30.43
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 70.15%
- ROIC
- 266.32%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $0+100.0%
- Op Income
- $-1,517,621
- Net Income
- $-1,552,744+60.4%
- EPS
- $-0.02+61.7%
- OCF Growth
- +32.0%
- FCF Growth
- +32.0%
- 52W High
- $1.72
- 52W Low
- $0.39
- 50D MA
- $0.85
- 200D MA
- $0.85
- Beta
- 1.76
- RSI (14)
- 53
- Avg Volume
- 60.04K
No earnings-call transcripts are available for ARCH.V yet.
- Free Float
- 78.2%
- Shares Outstanding
- 67.93M
- Float Shares
- 53.11M
Our ARCH.V coverage
Recent articles, reports, and earnings notes.
No research on ARCH.V yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ARCH.V report →